目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 43)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SEGMENTATION
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 47)
2.1 RESEARCH DATA
FIGURE 1 DNA DIAGNOSTICS MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 DNA DIAGNOSTICS INDUSTRY: REVENUE SHARE ANALYSIS
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.2.2 TOP-DOWN APPROACH
FIGURE 6 MARKET: TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
2.8 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT
2.9 RECESSION IMPACT ON MARKET

3 EXECUTIVE SUMMARY (Page No. - 60)
FIGURE 8 DNA DIAGNOSTICS MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
FIGURE 9 DNA DIAGNOSTICS INDUSTRY, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 10 MARKET, BY SPECIMEN, 2024 VS. 2029 (USD MILLION)
FIGURE 11 MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 12 MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 13 GEOGRAPHIC SNAPSHOT OF MARKET

4 PREMIUM INSIGHTS (Page No. - 65)
4.1 DNA DIAGNOSTICS MARKET OVERVIEW
FIGURE 14 RISING PREVALENCE OF CHRONIC, GENETIC, AND INFECTIOUS DISEASES TO DRIVE MARKET
4.2 ASIA PACIFIC: DNA DIAGNOSTICS INDUSTRY, BY TECHNOLOGY AND COUNTRY (2023)
FIGURE 15 PCR SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
4.3 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 CHINA TO REGISTER HIGHEST GROWTH RATE IN MARKET FROM 2024 TO 2029
4.4 MARKET: REGIONAL MIX (2024-2029)
FIGURE 17 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.5 MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 18 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 69)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 DNA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of chronic, infectious, and genetic diseases
FIGURE 20 INCIDENCE OF CANCER, BY REGION, 2022 VS. 2030 VS. 2045 (MILLION)
5.2.1.2 Rising focus on R&D and increased funding by healthcare companies
5.2.1.3 Growing demand for early disease diagnosis and personalized medicine in developing countries
5.2.1.4 Technological advancements in DNA diagnostics industry
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies
5.2.2.2 High cost of DNA diagnostic instruments
5.2.2.3 Ethical and privacy concerns associated with DNA diagnosis
5.2.3 OPPORTUNITIES
5.2.3.1 Growing significance of companion diagnostics in drug development process
5.2.3.2 Increasing growth opportunities for DNA diagnostic companies in emerging economies
5.2.3.3 Advancements in bioinformatics and artificial intelligence in DNA diagnostics
5.2.3.4 Expansion of direct-to-consumer (DTC) genetic testing
5.2.4 CHALLENGES
5.2.4.1 Changing regulatory landscape for IVD and DNA diagnostics in US and European Union
5.2.4.2 Operational barriers and shortage of skills across major markets
5.2.4.3 Introduction of alternative technologies for disease detection and diagnosis
5.3 PRICING ANALYSIS
5.3.1 PRICING ANALYSIS, BY REGION
TABLE 2 AVERAGE SELLING PRICE OF DNA DIAGNOSTIC PRODUCTS, BY REGION, 2021-2023
5.3.2 PRICING ANALYSIS, BY PRODUCT
TABLE 3 PRICING ANALYSIS OF DNA DIAGNOSTIC PRODUCTS, 2021-2023
5.4 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS OF DNA DIAGNOSTICS INDUSTRY: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 22 MARKET: SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
FIGURE 23 MARKET: ECOSYSTEM ANALYSIS
5.6.1 MARKET: ROLE IN ECOSYSTEM
5.7 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 24 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 REGULATORY ANALYSIS
5.8.1 NORTH AMERICA
5.8.1.1 US
5.8.1.2 Canada
5.8.2 EUROPE
TABLE 5 EUROPE: CLASSIFICATION OF DEVICES
5.8.3 ASIA PACIFIC
5.8.3.1 China
5.8.3.2 Japan
TABLE 6 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.8.3.3 India
5.8.4 LATIN AMERICA
5.8.4.1 Brazil
5.8.4.2 Mexico
5.8.5 MIDDLE EAST
5.8.6 AFRICA
5.8.7 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Polymerase chain reaction
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Sequencing technology
5.9.2.2 DNA microarrays
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Isothermal nucleic acid amplification technology
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 12 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 13 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2023 (USD MILLION)
5.11 PATENT ANALYSIS
FIGURE 25 PATENT ANALYSIS FOR DNA DIAGNOSTICS (JANUARY 2013-DECEMBER 2023)
5.11.1 LIST OF MAJOR PATENTS
5.12 KEY CONFERENCES AND EVENTS IN 2024-2025
TABLE 14 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2024-2025
5.13 PESTLE ANALYSIS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14.1 REVENUE SHIFT IN MARKET
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DNA DIAGNOSTIC END USERS
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF DNA DIAGNOSTIC END USERS (%)
5.15.2 BUYING CRITERIA
FIGURE 27 KEY BUYING CRITERIA FOR DNA DIAGNOSTIC END USERS
TABLE 16 KEY BUYING CRITERIA FOR DNA DIAGNOSTIC END USERS
5.16 INVESTMENT & FUNDING SCENARIO
FIGURE 28 MARKET: INVESTMENT & FUNDING SCENARIO

6 DNA DIAGNOSTICS MARKET, BY OFFERING (Page No. - 103)
6.1 INTRODUCTION
TABLE 17 DNA DIAGNOSTICS INDUSTRY, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 18 PRICE OF DNA DIAGNOSTIC PRODUCTS (2023)
6.2 REAGENTS & KITS
6.2.1 RECURRENT PURCHASE FOR DIAGNOSTICS TO PROPEL MARKET
TABLE 19 DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 20 NORTH AMERICA: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 21 EUROPE: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 23 LATIN AMERICA: DNA DIAGNOSTIC REAGENTS & KITS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET
TABLE 24 KEY INSTRUMENTS AVAILABLE IN MARKET
TABLE 25 DNA DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 26 NORTH AMERICA: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 27 EUROPE: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 29 LATIN AMERICA: DNA DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
6.4 SERVICES & SOFTWARE
6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE GROWTH
TABLE 30 DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 31 NORTH AMERICA: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 32 EUROPE: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 34 LATIN AMERICA: DNA DIAGNOSTIC SERVICES & SOFTWARE MARKET, BY COUNTRY, 2022-2029 (USD MILLION)

7 DNA DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 115)
7.1 INTRODUCTION
TABLE 35 DNA DIAGNOSTICS INDUSTRY, BY TECHNOLOGY, 2022-2029 (USD MILLION)
7.2 POLYMERASE CHAIN REACTION
7.2.1 GROWING USE OF PCR IN GENOMICS TO DRIVE MARKET
TABLE 36 MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022-2029 (USD MILLION)
TABLE 37 NORTH AMERICA: MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 38 EUROPE: MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 39 ASIA PACIFIC: MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 40 LATIN AMERICA: MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
7.3 MICROARRAY
7.3.1 INTRODUCTION OF DNA MICROARRAYS TO ACCELERATE GENE EXPRESSION AND DISEASE DIAGNOSIS
TABLE 41 MARKET FOR MICROARRAY, BY REGION, 2022-2029 (USD MILLION)
TABLE 42 NORTH AMERICA: MARKET FOR MICROARRAY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 43 EUROPE: MARKET FOR MICROARRAY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 44 ASIA PACIFIC: MARKET FOR MICROARRAY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 45 LATIN AMERICA: MARKET FOR MICROARRAY, BY COUNTRY, 2022-2029 (USD MILLION)
7.4 IN SITU HYBRIDIZATION
7.4.1 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET
TABLE 46 MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022-2029 (USD MILLION)
TABLE 47 NORTH AMERICA: MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 48 EUROPE: MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 49 ASIA PACIFIC: MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 50 LATIN AMERICA: MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
7.5 SEQUENCING
7.5.1 INCREASING USE OF NEXT-GENERATION SEQUENCING IN CANCER DIAGNOSIS TO FUEL MARKET
TABLE 51 MARKET FOR SEQUENCING, BY REGION, 2022-2029 (USD MILLION)
TABLE 52 NORTH AMERICA: MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 53 EUROPE: MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 54 ASIA PACIFIC: MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 55 LATIN AMERICA: MARKET FOR SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
7.6 MASS SPECTROSCOPY
7.6.1 TECHNOLOGICAL ADVANCEMENTS IN MASS SPECTROMETERS TO DRIVE ADOPTION
TABLE 56 MARKET FOR MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION)
TABLE 57 NORTH AMERICA: MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 58 EUROPE: MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 59 ASIA PACIFIC: MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 60 LATIN AMERICA: MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
7.7 OTHER TECHNOLOGIES
TABLE 61 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 62 NORTH AMERICA: MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 63 EUROPE: MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 64 ASIA PACIFIC: MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 65 LATIN AMERICA: MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)

8 DNA DIAGNOSTICS MARKET, BY SPECIMEN (Page No. - 135)
8.1 INTRODUCTION
TABLE 66 DNA DIAGNOSTICS INDUSTRY, BY SPECIMEN, 2022-2029 (USD MILLION)
8.2 BLOOD, SERUM, AND PLASMA
8.2.1 UTILIZATION OF BLOOD SAMPLES IN DETECTING AND MANAGING INFECTIOUS DISEASES TO DRIVE MARKET
TABLE 67 MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY REGION, 2022-2029 (USD MILLION)
TABLE 68 NORTH AMERICA: MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 69 EUROPE: MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 70 ASIA PACIFIC: MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 71 LATIN AMERICA: MARKET FOR BLOOD, SERUM, AND PLASMA SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
8.3 URINE
8.3.1 NONINVASIVE NATURE OF URINE SAMPLES TO FUEL SEGMENT GROWTH
TABLE 72 MARKET FOR URINE SPECIMENS, BY REGION, 2022-2029 (USD MILLION)
TABLE 73 NORTH AMERICA: MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 74 EUROPE: MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 75 ASIA PACIFIC: MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 76 LATIN AMERICA: MARKET FOR URINE SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
8.4 OTHER SPECIMENS
TABLE 77 MARKET FOR OTHER SPECIMENS, BY REGION, 2022-2029 (USD MILLION)
TABLE 78 NORTH AMERICA: MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 79 EUROPE: MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 80 ASIA PACIFIC: MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 81 LATIN AMERICA: MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2022-2029 (USD MILLION)

9 DNA DIAGNOSTICS MARKET, BY APPLICATION (Page No. - 145)
9.1 INTRODUCTION
TABLE 82 DNA DIAGNOSTICS INDUSTRY, BY APPLICATION, 2022-2029 (USD MILLION)
9.2 INFECTIOUS DISEASE DIAGNOSTICS
TABLE 83 MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 84 MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 85 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 86 EUROPE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 87 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 88 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
9.2.1 HEPATITIS
9.2.1.1 Increasing adoption of advanced technologies for diagnosis of hepatitis B to drive growth
TABLE 89 MARKET FOR HEPATITIS, BY REGION, 2022-2029 (USD MILLION)
TABLE 90 NORTH AMERICA: MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 91 EUROPE: MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 92 ASIA PACIFIC: MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 93 LATIN AMERICA: MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
9.2.2 HIV
9.2.2.1 Increasing prevalence of HIV to propel market
TABLE 94 MARKET FOR HIV, BY REGION, 2022-2029 (USD MILLION)
TABLE 95 NORTH AMERICA: MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 96 EUROPE: MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 97 ASIA PACIFIC: MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 98 LATIN AMERICA: MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
9.2.3 CT/NG
9.2.3.1 Increasing prevalence of CT/NG infections to support market growth
TABLE 99 MARKET FOR CT/NG, BY REGION, 2022-2029 (USD MILLION)
TABLE 100 NORTH AMERICA: MARKET FOR CT/NG, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 101 EUROPE: MARKET FOR CT/NG, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 102 ASIA PACIFIC: MARKET FOR CT/NG, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 103 LATIN AMERICA: MARKET FOR CT/NG, BY COUNTRY, 2022-2029 (USD MILLION)
9.2.4 HPV
9.2.4.1 Technological advancements for preventing HPV infections to drive market
TABLE 104 MARKET FOR HPV, BY REGION, 2022-2029 (USD MILLION)
TABLE 105 NORTH AMERICA: MARKET FOR HPV, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 106 EUROPE: MARKET FOR HPV, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 107 ASIA PACIFIC: MARKET FOR HPV, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 108 LATIN AMERICA: MARKET FOR HPV, BY COUNTRY, 2022-2029 (USD MILLION)
9.2.5 OTHER INFECTIOUS DISEASES
TABLE 109 MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
TABLE 110 NORTH AMERICA: MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 111 EUROPE: MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 112 ASIA PACIFIC: MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 113 LATIN AMERICA: MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
9.3 ONCOLOGY TESTING
9.3.1 GROWING SIGNIFICANCE OF PRECISION MEDICINE AND PERSONALIZED APPROACHES IN CANCER CARE TO DRIVE MARKET
TABLE 114 MARKET FOR ONCOLOGY TESTING, BY REGION, 2022-2029 (USD MILLION)
TABLE 115 NORTH AMERICA: MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 116 EUROPE: MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 117 ASIA PACIFIC: MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 118 LATIN AMERICA: MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
9.4 MYOGENIC DISORDERS
9.4.1 DIAGNOSIS OF VARIOUS MYOGENIC DISORDERS THROUGH DNA TESTING TO PROPEL MARKET
TABLE 119 MARKET FOR MYOGENIC DISORDERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 120 NORTH AMERICA: MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 121 EUROPE: MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 122 ASIA PACIFIC: MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 123 LATIN AMERICA: MARKET FOR MYOGENIC DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
9.5 PRENATAL
9.5.1 INCREASING DEMAND FOR EARLY DETECTION OF GENETIC DISORDERS TO BOOST MARKET GROWTH
TABLE 124 MARKET FOR PRENATAL, BY REGION, 2022-2029 (USD MILLION)
TABLE 125 NORTH AMERICA: MARKET FOR PRENATAL, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 126 EUROPE: MARKET FOR PRENATAL, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 127 ASIA PACIFIC: MARKET FOR PRENATAL, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 128 LATIN AMERICA: MARKET FOR PRENATAL, BY COUNTRY, 2022-2029 (USD MILLION)
9.6 PREIMPLANTATION
9.6.1 GROWING NUMBER OF FERTILITY CLINICS AND IVF CENTERS TO PROPEL MARKET
TABLE 129 NUMBER OF PREIMPLANTATION TESTS PERFORMED, BY COUNTRY, 2022-2029
TABLE 130 MARKET FOR PREIMPLANTATION, BY REGION, 2022-2029 (USD MILLION)
TABLE 131 NORTH AMERICA: MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 132 EUROPE: MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 133 ASIA PACIFIC: MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 134 LATIN AMERICA: MARKET FOR PREIMPLANTATION, BY COUNTRY, 2022-2029 (USD MILLION)
9.7 OTHER APPLICATIONS
TABLE 135 MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
TABLE 136 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 137 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 139 LATIN AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)

10 DNA DIAGNOSTICS MARKET, BY END USER (Page No. - 178)
10.1 INTRODUCTION
TABLE 140 DNA DIAGNOSTICS INDUSTRY, BY END USER, 2022-2029 (USD MILLION)
10.2 DIAGNOSTIC LABORATORIES
10.2.1 INCREASED OUTSOURCING OF DIAGNOSTIC TESTS BY HOSPITALS TO DRIVE MARKET
TABLE 141 MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 142 NORTH AMERICA: MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 143 EUROPE: MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 144 ASIA PACIFIC: MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 145 LATIN AMERICA: MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
10.3 HOSPITALS & CLINICS
10.3.1 GREATER NUMBER OF HOSPITALS AND HIGHER GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST GROWTH
TABLE 146 MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 147 NORTH AMERICA: MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 148 EUROPE: MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 149 ASIA PACIFIC: MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 150 LATIN AMERICA: MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
10.4 OTHER END USERS
TABLE 151 MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 152 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 153 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 154 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 155 LATIN AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)

11 DNA DIAGNOSTICS MARKET, BY REGION (Page No. - 188)
11.1 INTRODUCTION
TABLE 156 DNA DIAGNOSTICS INDUSTRY, BY REGION, 2022-2029 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: DNA DIAGNOSTICS MARKET SNAPSHOT
TABLE 157 NORTH AMERICA: MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 158 NORTH AMERICA: MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 159 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 160 NORTH AMERICA: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 161 NORTH AMERICA: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 162 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 163 NORTH AMERICA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 Increasing prevalence of infectious diseases and cancer to drive market
TABLE 164 US: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 165 US: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 166 US: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 167 US: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 168 US: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 169 US: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 170 US: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Rising prevalence of cancer and availability of healthcare funding to support market growth
TABLE 171 CANADA: CANCER DEATHS, BY TYPE, 2024 (%)
TABLE 172 CANADA: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 173 CANADA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 174 CANADA: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 175 CANADA: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 176 CANADA: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 177 CANADA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 178 CANADA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3 EUROPE
TABLE 179 EUROPE: DNA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 180 EUROPE: MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 181 EUROPE: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 182 EUROPE: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 183 EUROPE: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 184 EUROPE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 185 EUROPE: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Favorable government policies and rising per capita disposable income to propel market
TABLE 186 GERMANY: INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 187 GERMANY: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 188 GERMANY: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 189 GERMANY: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 190 GERMANY: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 191 GERMANY: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 192 GERMANY: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.3 UK
11.3.3.1 Growing number of accredited diagnostic laboratories to drive market
TABLE 193 UK: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 194 UK: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 195 UK: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 196 UK: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 197 UK: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 198 UK: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Rising R&D expenditure and increasing demand for early disease diagnosis to augment market
TABLE 199 FRANCE: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 200 FRANCE: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 201 FRANCE: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 202 FRANCE: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 203 FRANCE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 204 FRANCE: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Adoption of advanced diagnostic technologies to support market growth
TABLE 205 ITALY: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 206 ITALY: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 207 ITALY: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 208 ITALY: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 209 ITALY: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 210 ITALY: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players
TABLE 211 SPAIN: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 212 SPAIN: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 213 SPAIN: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 214 SPAIN: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 215 SPAIN: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 216 SPAIN: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 217 REST OF EUROPE: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 218 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 219 REST OF EUROPE: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 220 REST OF EUROPE: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 221 REST OF EUROPE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 222 REST OF EUROPE: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 30 ASIA PACIFIC: DNA DIAGNOSTICS MARKET SNAPSHOT
TABLE 223 ASIA PACIFIC: MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 224 ASIA PACIFIC: MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 225 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 226 ASIA PACIFIC: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 227 ASIA PACIFIC: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 228 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 229 ASIA PACIFIC: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.1 ASIA PACIFIC: RECESSION IMPACT
11.4.2 JAPAN
11.4.2.1 Universal healthcare reimbursement policy to support market growth
TABLE 230 JAPAN: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 231 JAPAN: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 232 JAPAN: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 233 JAPAN: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 234 JAPAN: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 235 JAPAN: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.3 CHINA
11.4.3.1 Rapid economic growth and greater public access to modern healthcare to drive market
TABLE 236 CHINA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 237 CHINA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 238 CHINA: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 239 CHINA: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 240 CHINA: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 241 CHINA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 242 CHINA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Increased private & public investments and large patient population to drive market
TABLE 243 INDIA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 244 INDIA: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 245 INDIA: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 246 INDIA: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 247 INDIA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 248 INDIA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.4.5 REST OF ASIA PACIFIC
TABLE 249 REST OF ASIA PACIFIC: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 250 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 251 REST OF ASIA PACIFIC: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 252 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 253 REST OF ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 254 REST OF ASIA PACIFIC: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.5 LATIN AMERICA
TABLE 255 LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 256 LATIN AMERICA: MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 257 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 258 LATIN AMERICA: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 259 LATIN AMERICA: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 260 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 261 LATIN AMERICA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.5.1 LATIN AMERICA: RECESSION IMPACT
11.5.2 BRAZIL
11.5.2.1 Improving healthcare infrastructure and stringent regulations to drive market
TABLE 262 BRAZIL: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 263 BRAZIL: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 264 BRAZIL: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 265 BRAZIL: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 266 BRAZIL: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 267 BRAZIL: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.5.3 MEXICO
11.5.3.1 Improving accessibility and affordability of healthcare services to aid market growth
TABLE 268 MEXICO: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 269 MEXICO: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 270 MEXICO: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 271 MEXICO: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 272 MEXICO: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 273 MEXICO: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.5.4 REST OF LATIN AMERICA
TABLE 274 REST OF LATIN AMERICA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 275 REST OF LATIN AMERICA: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 276 REST OF LATIN AMERICA: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 277 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 278 REST OF LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 279 REST OF LATIN AMERICA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET
TABLE 280 AFRICA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
TABLE 281 MIDDLE EAST & AFRICA: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 282 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 283 MIDDLE EAST & AFRICA: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 284 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 285 MIDDLE EAST & AFRICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 286 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
11.7 GCC COUNTRIES
11.7.1 INCREASED GOVERNMENT INVESTMENTS IN HEALTHCARE SECTOR TO DRIVE MARKET
TABLE 287 GCC COUNTRIES: DNA DIAGNOSTICS MARKET, BY OFFERING, 2022-2029 (USD MILLION)
TABLE 288 GCC COUNTRIES: MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 289 GCC COUNTRIES: MARKET, BY SPECIMEN, 2022-2029 (USD MILLION)
TABLE 290 GCC COUNTRIES: MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 291 GCC COUNTRIES: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 292 GCC COUNTRIES: MARKET, BY END USER, 2022-2029 (USD MILLION)
11.7.2 GCC COUNTRIES: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE (Page No. - 261)
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN DNA DIAGNOSTICS MARKET
TABLE 293 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DNA DIAGNOSTICS INDUSTRY
12.3 REVENUE ANALYSIS
FIGURE 31 REVENUE ANALYSIS OF TOP PLAYERS IN DNA DIAGNOSTICS INDUSTRY, 2021-2023 (USD MILLION)
12.4 MARKET SHARE ANALYSIS
FIGURE 32 DNA DIAGNOSTICS IND USTRYSHARE ANALYSIS, BY KEY PLAYER (2023)
TABLE 294 DNA DIAGNOSTICS INDUSTRY: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 33 DNA DIAGNOSTICS INDUSTRY: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1 Company footprint
TABLE 295 DNA DIAGNOSTICS INDUSTRY: COMPANY FOOTPRINT
12.5.5.2 Offering footprint
TABLE 296 DNA DIAGNOSTICS INDUSTRY: OFFERING FOOTPRINT
12.5.5.3 Technology footprint
TABLE 297 DNA DIAGNOSTICS INDUSTRY: TECHNOLOGY FOOTPRINT
12.5.5.4 End-user footprint
TABLE 298 DNA DIAGNOSTICS INDUSTRY: END-USER FOOTPRINT
12.5.5.5 Region footprint
TABLE 299 DNA DIAGNOSTICS INDUSTRY: REGION FOOTPRINT
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 34 DNA DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
TABLE 300 DNA DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
12.7 VALUATION & FINANCIAL METRICS
FIGURE 35 EV/EBITDA OF KEY VENDORS
FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
12.8 BRAND/PRODUCT COMPARISON
FIGURE 37 DNA DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 301 DNA DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2024
12.9.2 DEALS
TABLE 302 DNA DIAGNOSTICS MARKET: DEALS, JANUARY 2021-MAY 2024
12.9.3 EXPANSIONS
TABLE 303 DNA DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021-MAY 2024
12.9.4 OTHER DEVELOPMENTS
TABLE 304 DNA DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024

13 COMPANY PROFILES (Page No. - 278)
(Business overview, Products/Solutions/Services offered, Recent Developments, MnM view, Key strengths, Strategic choices, Weaknesses and competitive threats) *
13.1 KEY PLAYERS
13.1.1 DANAHER
TABLE 305 DANAHER: COMPANY OVERVIEW
FIGURE 38 DANAHER: COMPANY SNAPSHOT (2023)
TABLE 306 DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 307 DANAHER: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2024
TABLE 308 DANAHER: DEALS, JANUARY 2021-MAY 2024
13.1.2 ILLUMINA, INC.
TABLE 309 ILLUMINA, INC.: COMPANY OVERVIEW
FIGURE 39 ILLUMINA INC.: COMPANY SNAPSHOT (2023)
TABLE 310 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 311 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2021-MAY 2024
TABLE 312 ILLUMINA, INC.: DEALS, JANUARY 2021-MAY 2024
TABLE 313 ILLUMINA, INC.: EXPANSIONS, JANUARY 2021-MAY 2024
TABLE 314 ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024
13.1.3 F. HOFFMANN-LA ROCHE LTD.
TABLE 315 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
TABLE 316 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 317 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2024
TABLE 318 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-MAY 2024
13.1.4 BIOMÉRIEUX
TABLE 319 BIOMÉRIEUX: COMPANY OVERVIEW
FIGURE 41 BIOMÉRIEUX: COMPANY SNAPSHOT (2023)
TABLE 320 BIOMÉRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 321 BIOMÉRIEUX: PRODUCT APPROVALS, JANUARY 2021-MAY 2024
13.1.5 HOLOGIC, INC.
TABLE 322 HOLOGIC, INC.: COMPANY OVERVIEW
FIGURE 42 HOLOGIC, INC.: COMPANY SNAPSHOT (2023)
TABLE 323 HOLOGIC, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 324 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2021-MAY 2024
TABLE 325 HOLOGIC, INC.: DEALS, JANUARY 2021-MAY 2024
13.1.6 ABBOTT LABORATORIES
TABLE 326 ABBOTT LABORATORIES: COMPANY OVERVIEW
FIGURE 43 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023)
TABLE 327 ABBOTT LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 328 ABBOTT LABORATORIES: PRODUCT APPROVALS, JANUARY 2021-MAY 2024
TABLE 329 ABBOTT LABORATORIES: DEALS, JANUARY 2021-MAY 2024
13.1.7 THERMO FISHER SCIENTIFIC INC.
TABLE 330 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 44 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
TABLE 331 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 332 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-MAY 2024
13.1.8 QIAGEN
TABLE 333 QIAGEN: COMPANY OVERVIEW
FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2023)
TABLE 334 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 335 QIAGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2024
TABLE 336 QIAGEN: DEALS, JANUARY 2021-MAY 2024
13.1.9 REVVITY, INC.
TABLE 337 REVVITY, INC.: COMPANY OVERVIEW
FIGURE 46 REVVITY, INC.: COMPANY SNAPSHOT (2023)
TABLE 338 REVVITY, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 339 REVVITY, INC.: PRODUCT LAUNCHES, JANUARY 2021-MAY 2024
TABLE 340 REVVITY, INC.: DEALS, JANUARY 2021-MAY 2024
13.1.10 MYRIAD GENETICS, INC.
TABLE 341 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
FIGURE 47 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023)
TABLE 342 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 343 MYRIAD GENETICS, INC.: PRODUCT APPROVALS, JANUARY 2021-MAY 2024
TABLE 344 MYRIAD GENETICS, INC.: DEALS, JANUARY 2021-MAY 2024
13.1.11 SIEMENS HEALTHINEERS AG
TABLE 345 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
FIGURE 48 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
TABLE 346 SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
*Details on Business overview, Products/Solutions/Services offered, Recent Developments, MnM view, Key strengths, Strategic choices, Weaknesses and competitive threats might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 BECTON, DICKINSON AND COMPANY
13.2.2 GRIFOLS, S.A.
13.2.3 QUIDELORTHO CORPORATION
13.2.4 AGILENT TECHNOLOGIES, INC.
13.2.5 DIASORIN S.P.A.
13.2.6 EXACT SCIENCES CORPORATION
13.2.7 GENETIC SIGNATURES
13.2.8 BIOCARTIS
13.2.9 TBG DIAGNOSTICS LIMITED
TABLE 347 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
13.2.10 VELA DIAGNOSTICS
TABLE 348 VELA DIAGNOSTICS: COMPANY OVERVIEW
13.2.11 AMOY DIAGNOSTICS CO., LTD.
TABLE 349 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
13.2.12 MOLBIO DIAGNOSTICS PVT. LTD.
TABLE 350 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW

14 APPENDIX (Page No. - 338)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS